Click here for LIPOSORBER Instructions for Use and safety information
Find Treatment Center

LIPOSORBER®: An Advanced Treatment Option for Familial Hypercholesterolemia (FH) and Primary FSGS

LIPOSORBER® provides hope when standard drug therapy fails. This advanced therapeutic system is a critical treatment option designed specifically for physicians managing complex patient populations. We offer information for physicians and clinical teams on integrating LIPOSORBER® into their practice for patients with severe Familial Hypercholesterolemia (FH) and Focal Segmental Glomerulosclerosis (FSGS).

For Your Familial Hypercholesterolemia (FH) Patients 

Consider LIPOSORBER for your FH patients when their lipid levels remain above the recommended therapeutic targets, even after maximum drug therapies (such as statins and PCSK9 inhibitors) have failed. The system is designed to effectively remove harmful atherogenic lipoproteins—the type strongly associated with serious cardiovascular disease and vascular complications in FH patients.

For Your Focal Segmental Glomerulosclerosis (FSGS) Patients

LIPOSORBER should be considered for your adult and pediatric primary FSGS patients in cases where:

  • Standard therapies have failed.
  • Or therapies are not well-tolerated.
  • Or FSGS recurs following a renal transplantation.

In a clinical study, LIPOSORBER® enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.

Practice Benefits
Offer a comprehensive
lipid-lowering treatment
line to your practice

BENEFITS

Find a Center
Locate a center
closest to you 

LOCATIONS

Resources
Review videos, physician
education materials &
other documents

RESOURCES

Key Takeaways for Healthcare Providers

LIPOSORBER® is more than just a last resort; it’s a comprehensive treatment line that enhances your practice’s ability to manage high-risk patients.

  • Offer a Comprehensive Solution: Integrate a powerful, non-drug therapy option for patients who have exhausted standard pharmacological approaches.
  • Clinically Proven Efficacy: Data supports its ability to induce remission in a significant portion of steroid-resistant FSGS cases.
  • High Patient Need: Addresses the urgent needs of patients with life-threatening complications from severe FH and recurring FSGS.

Ready to learn more about the clinical evidence and patient criteria? Review our physician education materials now.

References:

*Based on a study that took place over two (2) years.